Drug intelligence / Profile preview

Jingqianshu

Development stage: Unknown
Lead developer: Qinhuangdao Shanhaiguan Pharmaceutical
Administration: Oral

Overview

Jingqianshu is a Traditional Chinese Medicine (TCM) formulation, typically administered as granules, developed for the treatment of premenstrual syndrome (PMS). Developed by the Hebei University of Traditional Chinese Medicine, the drug is currently undergoing clinical evaluation to confirm its efficacy and safety in managing the physical and emotional symptoms associated with the premenstrual phase. As a botanical product, its therapeutic effect is attributed to the synergistic action of its constituent herbal extracts, which are traditionally used in Chinese medicine to regulate qi and soothe the liver, thereby addressing the underlying imbalances thought to cause PMS symptoms.

Brand names: Jingqianshu
Other names: Jingqianshu granules

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)

Beyond the preview

Go deeper on Jingqianshu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jingqianshu.

Explore the full profile